Tekmira Pharmaceuticals this week announced that the US Patent and Trademark Office has declared a patent interference for Alnylam Pharmaceuticals' US patent covering siRNAs against a key target for its phase I liver cancer drug ALN-VSP.

As part of an ongoing lawsuit between the companies, Tekmira has alleged that certain claims in the patent, No. 7,718,629, are invalid in light of a Tekmira patent application. The patent office will now determine the priority of the subject matter in Alnylam's patent with respect to Tekmira's intellectual property, it said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.